Galapagos NV
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
18 mar 2014 - 07:30
Statutory name
Galapagos NV
Title
Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego
Comments
- First selective small molecule ephrin receptor kinase inhibitor to enter development
- GLPG1790 has high efficacy against triple-negative breast cancer
- Potentially suitable for other ephrin-driven cancers
- GLPG1790 is fully proprietary to Galapagos
Date last update: 11 April 2026